| Sunrise Energy Metals Limited (SRL) ORDINARY FULLY PAID |
Materials |
$2,731 |
Change in substantial holding
|
3 Feb 2026 9:04AM |
$10.420 |
$17.750 |
risen by
70.35%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$27 |
1AI Corporate Presentation
|
3 Feb 2026 9:04AM |
$0.020 |
$0.014 |
fallen by
32.50%
|
|
| Commonwealth Bank of Australia (CBA) ORDINARY FULLY PAID |
Financials |
$276,155 |
Items impacting CBA's financial reporting
|
3 Feb 2026 9:03AM |
$151.480 |
$165.020 |
risen by
8.94%
|
|
| Unico Silver Limited (USL) ORDINARY FULLY PAID |
Materials |
$400 |
Application for quotation of securities - USL
|
3 Feb 2026 9:03AM |
$0.810 |
$0.630 |
fallen by
22.22%
|
|
| Great Divide Mining Ltd (GDM) ORDINARY FULLY PAID |
Materials |
$24 |
Trading Halt
|
3 Feb 2026 9:02AM |
$0.420 |
$0.350 |
fallen by
16.67%
|
|
GDM - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Great Divide Mining Ltd.
- Halt related to potential capital raising.
- Securities to remain halted until 5 February 2026 or an announcement.
- Request authorized by the Board of Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$14 |
Significant Gallium Extensions identified at Block 3
|
3 Feb 2026 9:02AM |
$0.057 |
$0.040 |
fallen by
29.82%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- High-resolution magnetic survey indicates the gallium resource at Block 3 extends another 3.5km.
- Current JORC Resource of 2,700t of gallium trioxide is open for expansion.
- Potential for significant inventory increase along a 400m corridor.
- Nimy in discussions to access $1.2B Federal Government critical minerals fund.
- Strategic Metallurgy appointed for high-grade gallium concentrate test work.
- Exploration targets defined to a total of 26Mt at 100g/t Ga2O3 and 100Mt at 810ppm TREO.
- Nimy collaborating with M2i Global for U.S. market supply chain.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$220 |
2026 Tunkillia Development Drilling Programs Begin
|
3 Feb 2026 9:00AM |
$1.130 |
$0.815 |
fallen by
27.88%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Barton Gold Holdings Limited commences the 2026 Tunkillia development drilling program.
- The program includes 28,000m of reverse circulation drilling and 3,000m of diamond drilling.
- Aims to convert remaining open pit mineralisation to JORC (2012) Indicated category.
- Targeting a pre-feasibility study and Mining Lease application by the end of 2026.
- Current gold and silver prices are higher than past estimates, enhancing project economics.
- Objective to achieve a gold production target of 150,000 ounces annually.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sparc Technologies Limited (SPN) ORDINARY FULLY PAID |
Materials |
$35 |
Sparc Partner with AIML on AI Corrosion Assessment
|
3 Feb 2026 8:59AM |
$0.230 |
$0.295 |
risen by
28.26%
|
|
SPN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sparc Technologies partners with AIML for AI software development.
- The software aims to enhance protective coatings performance assessment.
- Utilizes advanced computer vision and machine learning techniques.
- Successful proof-of-concept under ISO 12944 corrosion boundary testing.
- Target market includes approximately 850 global labs.
- Software expected to replace outdated manual corrosion assessment methods.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Praemium Limited (PPS) ORDINARY FULLY PAID |
Information Technology |
$336 |
HY2026 Results Presentation
|
3 Feb 2026 8:58AM |
$0.755 |
$0.690 |
fallen by
8.61%
|
|
| Xpedra Resources Limited (XPD) ORDINARY FULLY PAID |
Materials |
$16 |
Appointment of Managing Director
|
3 Feb 2026 8:57AM |
$0.024 |
$0.022 |
fallen by
8.33%
|
|
XPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Scott Funston appointed as Managing Director of Xpedra Resources Limited.
- Xpedra to start maiden drilling program at Springfield Gold Deposit, NSW.
- Scott Funston has significant experience in the resources sector.
- His remuneration includes $250,000 plus superannuation and performance-based incentives.
- Performance Rights issuance subject to shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$703 |
Oklahoma Heart Institute to Become 4th US VISABL-AFL Site
|
3 Feb 2026 8:57AM |
$1.950 |
$1.990 |
risen by
2.05%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Oklahoma Heart Institute (OHI) has joined Imricor’s VISABL-AFL clinical trial.
- OHI is the fourth U.S. site in the VISABL-AFL trial, alongside University of Virginia, Virginia Commonwealth University, and Johns Hopkins University.
- OHI's participation aims to accelerate patient recruitment for the VISABL-AFL trial to support U.S. FDA approval.
- OHI has established cardiology-owned MRI facilities, reducing organizational barriers to adoption.
- Procedures at OHI are expected to start in March.
- Dr. Edward T. Martin is the Principal Investigator for VISABL-AFL at OHI.
- Dr. Martin is a Master of the Society for Cardiovascular Magnetic Resonance.
- Imricor’s CEO, Steve Wedan, highlights the sophisticated cardiology-led model of care at OHI.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xpedra Resources Limited (XPD) ORDINARY FULLY PAID |
Materials |
$16 |
Investor Presentation
|
3 Feb 2026 8:56AM |
$0.024 |
$0.022 |
fallen by
8.33%
|
|
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$28 |
Q2 FY26 Investor Update and Q&A - Presentation Materials
|
3 Feb 2026 8:55AM |
$0.440 |
$0.385 |
fallen by
12.50%
|
|
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$25 |
Regulatory Submissions Lodged for Felix
|
3 Feb 2026 8:55AM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Memphasys lodged submission for Felixâ„¢ System on ARTG with expected TGA approval by April 2026.
- Submission lodged with CDSCO in India for regulatory approval, with review expected in six months.
- Immediate commercial sales pathway in UK under CE Mark; no UKCA mark required during the transition.
- Australia performed over 103,556 ART cycles in 2023; Felixâ„¢ is positioned for fresh cycle usage.
- India's IVF market is growing rapidly, offering significant potential for Felixâ„¢ with 300,000 cycles annually.
- The UK market supports both NHS-funded and private clinic networks, suitable for Felixâ„¢ deployment.
- Memphasys executed a supply agreement with Andrology Center in India with activation upon CDSCO approval.
- Felixâ„¢ System combines electrophoresis and size-exclusion membranes for enhanced sperm quality.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Catalina Resources Ltd (CTN) ORDINARY FULLY PAID |
Materials |
$9 |
Breakaway Dam and Evanston Project Updates
|
3 Feb 2026 8:53AM |
$0.092 |
$0.050 |
fallen by
45.65%
|
|
CTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Breakaway Dam confirmed as a copper-rich VMS system.
- Approximately 3,000 meters of RC drilling planned.
- Tenement consolidation to secure contiguous land position.
- Phase 1 drilling at Leghorn Prospect confirms geological model.
- Potential for additional sulphide development at Breakaway Dam.
- Catalina to refine geological model and expand exploration efforts.
- Forward exploration program prioritised following successful 2025 campaign.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$378 |
South Erregulla Power Project
|
3 Feb 2026 8:50AM |
$0.100 |
$0.105 |
risen by
5%
|
|
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$46 |
Q2 FY26 Investor Update and Q&A - Presentation Materials
|
3 Feb 2026 8:50AM |
$0.390 |
$0.350 |
fallen by
10.26%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$23 |
Q2 FY26 Investor Update and Q&A - Presentation Materials
|
3 Feb 2026 8:49AM |
$0.685 |
$0.510 |
fallen by
25.55%
|
|
| Jade Gas Holdings Limited (JGH) ORDINARY FULLY PAID |
Energy |
$237 |
Monthly Operations Report - January 2026
|
3 Feb 2026 8:48AM |
$0.026 |
$0.115 |
risen by
342.31%
|
|
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$197 |
AROA Business Update Presentation
|
3 Feb 2026 8:46AM |
$0.640 |
$0.570 |
fallen by
10.94%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- Aroa Biosurgery Limited presented a business update on 3 February 2026.
- The presentation is intended for investor education and not as an offer of securities.
- The Myriad Trauma Study, a large multicenter observational study, is ongoing with 450 patients enrolled.
- The Symphony product has undergone reimbursement changes expected to disrupt the market.
- The presentation includes forward-looking statements and financial guidance.
- Guidance for the financial year includes a revenue target of NZ$92-100 million and EBITDA of NZ$5-8 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$28 |
Initial Director's Interest Notice
|
3 Feb 2026 8:45AM |
$0.120 |
$0.075 |
fallen by
37.50%
|
|
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$2,787 |
Change of Officer's Interest Notice
|
3 Feb 2026 8:45AM |
$81.570 |
$73.090 |
fallen by
10.40%
|
|
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$34 |
Rhythm Biosciences Signs Manufacturing Agreement
|
3 Feb 2026 8:45AM |
$0.150 |
$0.096 |
fallen by
36%
|
|
RHY - Price-sensitive ASX Announcement
Full Release
Key Points
- Rhythm Biosciences signs a manufacturing agreement with Quansys Biosciences.
- The agreement supports the commercial-scale production of ColoSTAT® reagent kits.
- ColoSTAT® is a blood-based test for early detection of colorectal cancer.
- Quansys operates ISO13485-certified manufacturing facilities.
- The partnership ensures scalable supply to meet market demands.
- The agreement follows two years of collaborative assay development.
- Rhythm Biosciences is based in Melbourne, Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$197 |
AROA Business Update
|
3 Feb 2026 8:45AM |
$0.640 |
$0.570 |
fallen by
10.94%
|
|
ARX - Price-sensitive ASX Announcement
Full Release
Key Points
- CMS implemented a single reimbursement rate for skin substitutes at US$127.14 per square centimetre.
- AROA's Symphony Randomised Control Trial is completed and will be published in FY27.
- Myriad study shows effective tissue coverage in trauma procedures with reduced cost of care.
- FY26 revenue guidance of NZ$92-100 million with normalised EBITDA of NZ$5-8 million.
- Aroa Biosurgery plans to leverage its Symphony product for outpatient settings in the US.
- The MASTRR study supports Myriad's effectiveness in complex trauma procedures.
- Aroa will host a webinar with CEO Brian Ward and CFO James Agnew on 3 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bellevue Gold Limited (BGL) ORDINARY FULLY PAID |
Materials |
$1,983 |
Change in substantial holding
|
3 Feb 2026 8:44AM |
$1.730 |
$1.330 |
fallen by
23.12%
|
|